Assess the Effect of Dehydroepiandrosterone (DHEA) or Other Androgenic Agents Over Markers of Ovarian Reserve

Laboratorios Andromaco S.A.94 enrolled

Overview

This study was conducted to evaluate the effect of a continuous administration of dehydroepiandrosterone (DHEA) or other androgenic agents on ovarian reserve markers in women with diminished ovarian reserve (ROD), such as antral follicle count (AFC) and anti-Müllerian hormone (AMH) concentrations.

Healthy women attending the clinic of the Mother and Health Research Institute (IDIMI) were invited to participate, if they could not become pregnant due to surgical sterilization, and if they presented no contraindications to use androgen therapy. Project Objectives : The general objective was to evaluate pharmacokinetic parameters of three vaginal rings containing DHEA, testosterone, or combination of both hormones in women. Secondary objectives were to assess effects on the hormonal profile, tolerability and incidence of adverse events. * DHEA and/or, testosterone levels * Estradiol, follicle stimulating hormone (FSH), sex hormone binding globulin (SHBG), androstenedione, morning cortisol, insulin growth factor 1 (IGF-1) levels * Tolerability and safety assessment by the use of the vaginal ring. * The incidence of adverse events

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

TRIPLE

Enrollment

Conditions

Healthy Women Infertility, Female

Interventions

DHEADRUG

DHEA 2.2 g in vaginal ring

Another Androgenic Agent (VRaA)DRUG

Testosterone 35 mg in vaginal ring

Fixed combination of 2 androgenic agents (VR2A)DRUG

DHEA 1.5 g/testosterone 25 mg fixed combination in vaginal ring

Eligibility

Sex: FEMALEMin age: 38 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Women between 38 and 45 years of age who have not used hormonal contraceptive methods at least for the past two months, or who have been surgically sterilized, with no contraindications for androgenic therapy. 2. Women with preserved menstrual cycles. 3. Women smoking less than 5 cigarettes daily. 4. Anti-Müllerian hormone (AMH) between 0.5-1.1 ng/mL 5. Total antral follicle count (AFC) 5-7 Exclusion Criteria: 1. Women receiving medications that interact with DHEA metabolism (Anastrozole, exemestane, Fulvestrant, Insulin, Letrozole, Tamoxifen, Triazolam). 2. Women with diabetes mellitus 3. Women with untreated or decompensated endocrine disorders 4. Women with a prior history of ovarian surgery or oophorectomy

Locations (1)

Mother and Health Research Institute (IDIMI), Faculty of Medicine, University of Chile

Santiago, International, Chile

Outcomes

Primary Outcomes

Effect of the association of DHEA plus testosterone over ovarian reserve markers

The ovarian reserve markers antral follicle count (AFC) and anti-Müllerian hormone (AMH) were determined before and after hormonal therapy to compare the levels of both hormones between mono- and combination therapy and to investigate a potentially synergistic effect of the association of DHEA plus testosterone.

Time frame: Before therapy start and up to 2 months thereafter

Secondary Outcomes

Plasma levels of sex hormone binding globulin (SHBG), androstenedione, morning cortisol, insulin growth factor 1 (IGF-1), testosterone, dehydroepiandrosterone, follicle stimulating hormone (FSH), and estradiol

A composite of hormones was measured and compared before and after hormonal therapy.

Time frame: Before therapy start and up to 2 months thereafter

Tolerability of using the vaginal ring

A questionnaire was used post insertion and post extraction of the vaginal ring to assess tolerability. The following was addressed: changes in vaginal discharge (never happened/no change/increased a little/increased much/changed color), vaginal infection (by fungi or bacteria: yes/no), burning (yes/no), odor (yes/no), pain (yes/no; if yes, assessed on a 1 to 10 scale for no pain to worst pain), discomfort (yes/no) or dryness (yes/no) of the vagina, changes (for couples) in the sexual relationship by the use of the vaginal ring (better/as always/with annoyance/with pain/did not have).

Time frame: After therapy start (vaginal ring insertion) and after 2 months (ring extraction)

Number of subjects with adverse events per treatment group

Adverse events were collected by non-leading questions.

Time frame: From therapy start to up to 2 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.